0.446
0.38%
0.0017
プレマーケット:
.45
0.004
+0.90%
Athira Pharma Inc (ATHA) 最新ニュース
Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC - Defense World
Wall Street SWOT: Athira Pharma stock faces crossroads after Alzheimer's trial setback - Investing.com
Athira Pharma Inc (ATHA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Athira Pharma stock plunges to 52-week low of $0.41 - Investing.com India
Athira Pharma stock plunges to 52-week low of $0.41 By Investing.com - Investing.com Canada
Taking a look at what insiders are doing to gauge the Athira Pharma Inc (ATHA)’s direction - Knox Daily
Check out these key findings about Athira Pharma Inc (ATHA) - SETE News
Was Athira Pharma Inc (ATHA)’s session last reading good? - US Post News
Athira Pharma to lay off 70% of workforce - PharmaLive
Athira Pharma Inc (ATHA) Becoming More Attractive for Investors - Knox Daily
Market Watch Highlights: Athira Pharma Inc (ATHA) Ends on an Downturn Note at 0.43 - The Dwinnex
Athira Pharma stock faces pivot and workforce cuts amid trial setbackMizuho - Investing.com Canada
Athira Pharma stock faces pivot and workforce cuts amid trial setbackMizuho - Investing.com India
Athira Pharma Inc [ATHA] Officer makes an insider purchase of 5,032 shares worth 1.0. - Knox Daily
Athira Pharma stock hits 52-week low at $0.46 amid market challenges - Investing.com
Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 8.7% in August - Defense World
Taking the lead: Athira Pharma Inc (ATHA) - SETE News
Athira Pharma Inc Inc. (ATHA) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Athira Pharma Inc (NASDAQ: ATHA): Slumped -75.09% In 2024, Outlook Stable - Stocks Register
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Athira Pharma lays off 70% of its staff as company shifts focus - The Business Journals
Athira Pharma to Cut About 70% of Workforce - MarketWatch
Athira Pharma to focus on ATH-1105 advancement, reduces workforce by 70% - TipRanks
Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring - GeekWire
Athira’s Alzheimer’s Drug Fails in Later-stage Clinical Trial - Being Patient
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - GlobeNewswire
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - StockTitan
Market Recap Check: Athira Pharma Inc (ATHA)’s Negative Finish at 0.51, Up/Down -4.18 - The Dwinnex
Is Athira Pharma Inc (ATHA) a opportunity to investors? - US Post News
Athira Pharma Inc [ATHA] Investment Guide: What You Need to Know - Knox Daily
Market Update: Athira Pharma Inc (ATHA) Sees Positive Movement, Closing at 0.51 - The Dwinnex
AdPha urges HTA reform - Pharmacy Daily
Fosgonimeton fails to meet goal in Alzheimer’s clinical trial: Data - Alzheimer's News Today
Athira Pharma stock plunges to 52-week low of $0.46 By Investing.com - Investing.com Australia
Ready to Jump After Recent Trade: Athira Pharma Inc (ATHA) - SETE News
Athira Pharma stock plunges to 52-week low of $0.46 - Investing.com
Rodman & Renshaw downgrades Athira Pharma Inc (ATHA) rating to a Neutral - Knox Daily
ATHA’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Recent Insider Activity Suggests Potential Gains for Athira Pharma Inc (ATHA) - Knox Daily
Closing Bell Recap: Athira Pharma Inc (ATHA) Ends at 0.54, Reflecting a -3.65 Downturn - The Dwinnex
StockWatch: Athira Pays Price as Alzheimer’s Candidate Fails Trial - Genetic Engineering & Biotechnology News
Athira Pharma executive sells shares on clinical trial milestone By Investing.com - Investing.com Australia
Athira Pharma (ATHA) Stock Price, News & Analysis - MarketBeat
Athira Pharma COO Rachel Lenington sells shares worth $1,429 - Investing.com India
Athira plunges as Alzheimer’s trial setback leads to downgrades - MSN
Athira Pharma CEO sells over $2.8k in company stock - Investing.com
Athira Pharma COO Rachel Lenington sells shares worth $1,429 By Investing.com - Investing.com Canada
Athira Pharma executive sells shares on clinical trial milestone By Investing.com - Investing.com UK
Athira Pharma executive sells shares worth $1,429 By Investing.com - Investing.com UK
Athira Pharma tanks as fosgonimeton misses in Alzheimer’s trial | Pharmaceutical | The Pharmaletter - The Pharma Letter
Athira Pharma (NASDAQ:ATHA) Downgraded by BTIG Research to Neutral - Defense World
Athira Pharma (NASDAQ:ATHA) Downgraded to Neutral at Rodman & Renshaw - Defense World
Athira Pharma (NASDAQ:ATHA) Downgraded by JMP Securities to “Market Perform” - Defense World
Athira Pharma general counsel acquires shares, sells for $1.4k - Investing.com
Athira Pharma stock hits 52-week low at $0.7 amid market shifts - Investing.com
Athira Pharma stock hits 52-week low at $0.7 amid market shifts - Investing.com India
Athira’s Fosgonimeton Fails In Phase II/III LIFT-AD Trial, Future Uncertain - Scrip
Goldman Sachs moves Athira Pharma to Not Rated - TipRanks
Athira stock plunges on Alzheimer’s trial setback (NASDAQ:ATHA) - Seeking Alpha
Rodman & Renshaw Downgrades Athira Pharma (NASDAQ:ATHA) to Neutral - MarketBeat
Mizuho maintains Outperform rating on Athira Pharma shares despite trial miss - Investing.com Canada
Alzheimer’s Trial Failure Sends Athira Stock Down 75% - Barron's
Athira’s stock topples after Alzheimer’s drug flops in Phase II/III trial - Pharmaceutical Technology
Athira’s stock topples after Alzheimer’s drug flops in Phase II/III trial - Clinical Trials Arena
Athira’s stock topples after Alzheimer’s drug flops in Phase II/III trial - Yahoo Finance
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - Yahoo Finance
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks - AOL
Athira’s Small Molecule Injection for Alzheimer’s Flops in Phase II/III Study - BioSpace
Athira Pharma stock hits 52-week low at $0.7 amid market shifts - Investing.com UK
Why Is Athira Pharma Stock Plunging On Wednesday?Athira Pharma (NASDAQ:ATHA) - Benzinga
Athira Pharma tumbles after Alzheimer's drug fails trial - XM
Athira Pharma shares downgraded to neutral by BTIG - Investing.com
Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial - ETHealthWorld
Athira Pharma downgraded to Neutral from Buy at BTIG - TipRanks
Stocks to Watch: Sportsman's Warehouse Holdings, PagerDuty, Athira Pharma - MarketWatch
Drug aimed at strengthening neurons to treat Alzheimer’s fails in trial - STAT
大文字化:
|
ボリューム (24 時間):